Table 3.
Relationship between frequency of prescribing FDC antihypertensive medicines and barriers and facilitators.
|
| ||||
|---|---|---|---|---|
| BARRIER OR FACILITATOR | β | 95% CONFIDENCE INTERVAL | P-VALUE | P-VALUE (95% CI) FOR INTERACTION WITH COUNTRY INCOME LEVEL |
|
| ||||
| Appointment time | –0.06 | –0.43 to 0.31 | 0.74 | |
|
| ||||
| Access | –0.58 | –0.86 to –0.29 | <0.001 | 0.22 (–0.28 to 0.71) |
|
| ||||
| Confidence in blood pressure (BP) measurement | –0.35 | –0.70 to 0.01 | 0.06 | |
|
| ||||
| Cost to medical practice | –0.81 | –1.14 to –0.50 | <0.001 | 0.02 (–0.57 to 0.61) |
|
| ||||
| Side effects | –0.32 | –0.74 to 0.10 | 0.13 | |
|
| ||||
| Adherence | 0.00 | –0.43 to 0.43 | 0.99 | |
|
| ||||
| Clinician nudge | 0.22 | –0.22 to 0.66 | 0.33 | |
|
| ||||
| Education | –0.10 | –0.50 to 0.30 | 0.62 | |
|
| ||||
| Additional BP measures data | –0.17 | –0.56 to 0.23 | 0.40 | |
|
| ||||
| Health literacy | 0.11 | –0.29 to 0.50 | 0.59 | |
|
| ||||